What Is Lipoprotein(a) — and Should You Test It in Singapore?

Every year, Singaporeans go for their annual cholesterol check. The report comes back with four numbers — total cholesterol, LDL, HDL, and triglycerides — and a note that says “within normal limits.”

Lipoprotein(a), or Lp(a), is a genetically inherited blood particle that independently increases cardiovascular risk — and is not measured in any of those four numbers.

For most people, most of the time, that is reassuring. But there is a cardiovascular risk marker that has nothing to do with those four numbers, that cannot be changed by diet or statins, and that most standard health screens in Singapore simply do not test. That marker is Lipoprotein(a) — Lp(a).

This article explains what Lp(a) is, why it matters, who should consider testing, and what to do with the result.

What is Lipoprotein(a)?

Lipoprotein(a) is a type of lipoprotein particle — a small package that carries cholesterol and fats through the bloodstream. What makes it distinct is an additional protein attached to it called apolipoprotein(a), or apo(a). This structure makes Lp(a) particles particularly prone to lodging in artery walls, accelerating plaque buildup — and increasing the risk of heart attack and stroke.

In Singapore, Lp(a) is not included in the Ministry of Health Screen for Life programme, nor in most private health screening packages. It requires a specific test request — which is why most Singaporeans have never had it measured.

Unlike LDL cholesterol, which responds to diet and medication, Lp(a) levels are approximately 90% genetically determined. You are largely born with a fixed Lp(a) level, and it stays relatively stable throughout your adult life. This means it behaves less like a lifestyle marker and more like an inherited risk factor — similar to a family history of heart disease.

Lp(a) levels vary enormously between individuals and across ethnic groups. Research suggests that South Asians and people of African descent tend to have higher population-level Lp(a) compared to East Asians and Europeans — though individual variation within any group is substantial.

Why is Lp(a) getting more attention now?

Lp(a) is not a new discovery. It has been studied since the 1960s. What has changed is the accumulation of large-scale genetic and epidemiological evidence linking elevated Lp(a) to outcomes that clinicians care about — heart attacks, stroke, and aortic valve disease — independent of other lipid markers.

Several large Mendelian randomisation studies have provided evidence that elevated Lp(a) is causally associated with cardiovascular disease, not merely correlated with it. This distinction matters. It means Lp(a) is not just a risk marker — it is a plausible mechanism.

The field of preventive cardiology has moved significantly in recent years toward measuring cardiovascular risk with greater precision — not just whether your LDL is elevated, but what types of particles are present, in what quantity, and over what timeframe. Lp(a) is central to that more precise picture.

Who should get an Lp(a) test?

In Singapore’s primary care setting, Lp(a) testing is most relevant for patients who:

• Have a family history of early cardiovascular disease — a first-degree relative who had a heart attack or stroke before the age of 60, particularly in the absence of obvious risk factors like hypertension or smoking
• Have had a cardiovascular event themselves at an age or severity that seems disproportionate to their standard risk profile
• Have borderline or modestly elevated LDL and are trying to understand their true cardiovascular risk before making a treatment decision
• Have been told their cholesterol is “fine” but have other concerning features — central obesity (excess fat carried around the abdomen rather than the hips), metabolic syndrome (a cluster of conditions including raised blood pressure, high blood sugar, and abnormal cholesterol that often appear together), strong family history
• Are taking a proactive longevity approach and want a complete baseline of their cardiovascular risk architecture

If a close blood relative has been found to have significantly elevated Lp(a), it is worth considering testing yourself — the same genetic variant is likely shared.

Can you lower Lipoprotein(a)?

This is where the clinical picture becomes more nuanced — and where honesty matters more than reassurance.

Lp(a) does not respond meaningfully to lifestyle changes. Diet modification, exercise, and weight loss — interventions that significantly lower LDL cholesterol — have minimal effect on Lp(a) levels. This can feel frustrating for patients who are used to being told that lifestyle changes address most cardiovascular risk.

Standard lipid-lowering medications have limited effect. Statins, the most widely prescribed lipid-lowering drugs, do not lower Lp(a) and may modestly increase it in some patients. Niacin lowers Lp(a) but has not demonstrated improved cardiovascular outcomes in trials and is rarely used in modern practice.

Targeted therapies are emerging. Several novel therapies specifically targeting Lp(a) are in late-stage clinical trials as of 2026. These include RNA-based approaches that inhibit Lp(a) production in the liver. Results so far are promising in terms of Lp(a) reduction, with outcome data anticipated over the coming years.

What this means practically is that if your Lp(a) is elevated, the clinical response is not to try to lower it through lifestyle — it is to identify and aggressively manage every other cardiovascular risk factor that is modifiable: blood pressure, insulin resistance, inflammation, smoking, ApoB-containing lipoproteins, and body composition.

How often should Lp(a) be tested?

Because Lp(a) is genetically determined and stable over a lifetime, the primary value is in establishing a baseline — ideally once in adulthood. Unlike markers such as insulin resistance or hsCRP that change with lifestyle, repeated Lp(a) testing in the same individual rarely changes the clinical picture.

The exception is in the context of monitoring patients on novel Lp(a)-lowering therapies as they become available. In that context, serial measurements to assess treatment response would be appropriate.

For most patients, the single most useful action is to know your number — and then to ensure that the rest of your cardiovascular risk profile is thoroughly assessed and managed in light of it.

What does an elevated Lp(a) result mean?

Lp(a) is typically reported in mg/dL or nmol/L. Broadly:

These thresholds are general guides, not hard clinical cutoffs. The significance of any Lp(a) level depends on the patient’s full risk profile — their age, blood pressure, insulin sensitivity, inflammatory markers, smoking history, and family history all contribute to the overall picture.

AMG clinical thresholds vs standard lab ranges

Standard lab reports often flag Lp(a) only above 75 nmol/L with no further guidance. At AMG, we interpret Lp(a) in the context of your full cardiovascular and metabolic profile — not as an isolated number.

Where can you test Lp(a) in Singapore?

Lp(a) is not included in standard Ministry of Health Screen for Life panels or in most private health screen packages. It requires a specific test request.

At Advantage Medical Group, Lp(a) is included in every VITAL Longevity Screen — alongside ApoB, HOMA-IR, hsCRP, and the full hormonal and physical function assessment. It is also available as a standalone add-on to a standard health screen if you want to begin with your lipid picture before committing to a full longevity assessment.

If you are unsure whether Lp(a) testing is relevant for your particular history and risk profile, a conversation with one of our GPs is the right starting point. There is no single marker that tells the whole story — but for the right patient, Lp(a) is one of the most important numbers they have never measured.